PRNewsWire
12 Dec 2025, 13:30 UTC · 39w ago
Verdict
Headline takes no side. We score RZLT −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Rezolute's Phase 3 sunRIZE trial for ersodetug failed to meet its primary endpoint, as the reduction in hypoglycemia events was not statistically significant compared to placebo.
So whatThe failure of a lead asset's pivotal Phase 3 trial destroys the core commercial thesis and valuation of a clinical-stage biotech, triggering severe stock repricing.
More negative than 99% of claims this week
Ersodetug also failed to meet its secondary endpoint assessing the change in average daily percent time in hypoglycemia by continuous glucose monitoring compared to placebo.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 98% of claims this week
An analyst downgraded Rezolute from outperform to neutral and slashed the price target from $12 to $1.
So whatA dramatic 90%+ target reduction from a sell-side analyst reflects and amplifies the total collapse in the stock's fundamental valuation floor.
More negative than 96% of claims this week
Hagens Berman has opened an investigation into whether Rezolute previously misled investors about ersodetug's efficacy and commercial prospects.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
Shares crashed 90% following the failure of a Phase 3 clinical trial and the launch of a shareholder investigation.
More negative than 88% of ticker scores this week
Facing a securities class action lawsuit.
More negative than 88% of ticker scores this week
Facing a securities class action lawsuit and an anti-monopoly probe.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
18h ago
+184.3%
Price is moving against the score
$3.98 vs $1.40 close before publication (Dec 11) · not market-adjusted
RZLT chart →
